Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).
[More]
Women who experience vulvodynia are more likely than those without the pain syndrome to have fibromyalgia, interstitial cystitis, and irritable bowel syndrome, research suggests.
[More]
Millions of women suffer from unexplained vulvar pain so severe it can make intercourse, exercise and even sitting unbearable. New research now shows that women with this painful vaginal condition known as vulvodynia are two to three times more likely to also have one or more other chronic pain conditions, including irritable bowel syndrome, fibromyalgia (musculoskeletal pain) and interstitial cystitis (bladder pain).
[More]
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.
[More]
Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.
[More]
Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.
[More]
Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation.
[More]
Lifescript.com, a women's health and wellness website headquartered in Mission Viejo, Calif., has launched a new online Fibromyalgia Health Center, designed to help women treat and reduce the frustrations and pain of fibromyalgia.
[More]
A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).
[More]
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, today reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.
[More]
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
[More]
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
[More]
The International Association for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (IACFS/ME), the largest group of physicians and researchers dedicated to chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), has released updated care guidelines directed at primary care physicians and other health care providers.
[More]
A recent study has shown that exercise can add years to a person's life. Still, as we age it can become more tedious and sometimes more difficult to exercise.
[More]
A growing body of evidence shows massage therapy can be effective for a variety of prevalent health conditions, including the pain of osteoarthritis of the knee, inflammation after exercise, chronic low back pain and fibromyalgia.
[More]
Pfizer Inc. announced today the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu.
[More]
The American Pain Society (APS), today honored the recipients of its sixth annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers.
[More]
Scientists at Weill Cornell Medical College have discovered that the single protein -- alpha 2 delta -- exerts a spigot-like function, controlling the volume of neurotransmitters and other chemicals that flow between the synapses of brain neurons. The study, published online in Nature, shows how brain cells talk to each other through these signals, relaying thoughts, feelings and action, and this powerful molecule plays a crucial role in regulating effective communication.
[More]
Pfizer Inc. announced today that it has stopped a Phase 3 clinical trial of Lyrica (pregabalin) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet. The decision follows review of a planned interim analysis of the study by the trial's external Data Monitoring Committee.
[More]
Pfizer Inc. announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline.
[More]